Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026
Ascendis Pharma announced it will share new long-term clinical data at the ASBMR 2026 conference, highlighting normalization of bone mass and microarchitecture in hypoparathyroidism patients treated with TransCon PTH over five years. The company also will present data on its achondroplasia programs, including improvements in growth and physical fun…